Journals / Fabad Eczacılık Bilimler Dergisi / 2026 / Cilt: 51 Sayı: 2

The Pharmacological and Chemical Profile of Vorinostat (SAHA): A Comprehensive Review

Zain Orfali(ANKARA UNIVERSITY, FACULTY OF PHARMACY, PHARMACY PR.)0000-0002-1810-7442
Zehra Arslan(ANKARA UNIVERSITY, FACULTY OF PHARMACY, PHARMACY PR.)0000-0001-9169-667X
Oya Bozdağ Dündar(ANKARA ÜNİVERSİTESİ, ECZACILIK FAKÜLTESİ, ECZACILIK MESLEK BİLİMLERİ BÖLÜMÜ, FARMASOTİK KİMYA ANABİLİM DALI)0000-0002-2240-8854
Pages
1041–1058
Publication Date
2026-08-31
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This article compiles and summarizes literature data on the synthesis, structure–activity relationships, physicochemical properties, as well as the pharmacological characteristics, mechanism of action, and pharmacokinetic profile of vorinostat.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Vorinostat (N-hydroxy-N′-phenyloctanediamide) is an HDAC inhibitor that targets HDAC enzymes.
📊
Key Findings & Data:Food and Drug Administration (FDA) approved vorinostat for use as a third-line treatment in patients with refractory and relapsed cutaneous T-cell lymphoma (CTCL).
💡
Conclusion & Impact:This article compiles and summarizes literature data on the synthesis, structure–activity relationships, physicochemical properties, as well as the pharmacological characteristics, mechanism of action, and pharmacokinetic profile of vorinostat.
🔬Design:Derleme
📍Scope:2006 Verileri
⚙️Variables:Anahtar Kelimeler: vorinostat · HDAC inhibitörü · sentez

Abstract

Vorinostat (N-hydroxy-N′-phenyloctanediamide) is an HDAC inhibitor that targets HDAC enzymes. In 2006, the U.S. Food and Drug Administration (FDA) approved vorinostat for use as a third-line treatment in patients with refractory and relapsed cutaneous T-cell lymphoma (CTCL). Vorinostat inhibits HDAC enzymes by chelating the zinc ion located in the catalytic site, leading to reprogramming of gene expression; this results in cell cycle arrest, suppression of proliferation, and induction of apoptosis in transformed cells. Current studies continue to investigate its potential applications against various cancer types, HIV, and parasitic infections. This article compiles and summarizes literature data on the synthesis, structure–activity relationships, physicochemical properties, as well as the pharmacological characteristics, mechanism of action, and pharmacokinetic profile of vorinostat.

Özet

Vorinostat (N-hidroksi-N'-feniloktandiamid), histon deasetilaz (HDAC) enzimlerini hedef alan HDAC inhibitörleri sınıfında yer alır. 2006 yılında, dirençli ve nükseden kutanöz T-hücreli lenfoma (CTCL) hastalarında üçüncü basamak tedavide kullanılmak üzere Amerika Birleşik Devletleri Gıda ve İlaç Dairesi (FDA) tarafından onay almıştır. Vorinostat, katalitik bölgede yer alan çinko iyonunu şelatlayarak HDAC enzimlerini inhibe eder bunun sonucunda gen ekspresyonu yeniden düzenlenir; hücre döngüsü durur, proliferasyon baskılanır ve transforme hücrelerde apoptoz indüklenir. Güncel araştırmalar; ilacın farklı kanser türleri, HIV ve paraziter enfeksiyonlara karşı potansiyel kullanımını incelemeye devam etmektedir. Bu makale, vorinostat’ın sentezi, yapı-aktivite ilişkileri, fiziko-kimyasal özelliklerinin yanı sıra farmakolojik özellikleri, etki mekanizması ve farmakokinetik profiline dair literatür bilgilerini bir araya getirerek özetlemektedir.

🔖

Cite This Article

Arslan, Z., Dündar, O. B. (2026). The Pharmacological and Chemical Profile of Vorinostat (SAHA): A Comprehensive Review. Fabad Eczacılık Bilimler Dergisi, Cilt: 51 Sayı: 2, 1041–1058. https://doi.org/10.55262/fabadeczacilik.1877769

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Alqosaibi, A. I., & Abdel-Ghany, S. (2023). Vorinostat induces G2/M cell cycle arrest in breast cancer cells via upregulation of PTEN. European Review for Medical and Pharmacological Sciences, 27(4), 1503–1511. doi: 10.26355/eurrev_202302_31391.